Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia
出版年份 2022 全文链接
标题
Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia
作者
关键词
-
出版物
Nature Communications
Volume 13, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-12
DOI
10.1038/s41467-021-27945-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles
- (2021) Petr O. Ilyinskii et al. Science Advances
- Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study
- (2021) Karen Liao et al. PLoS One
- Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles
- (2021) Petr O. Ilyinskii et al. Frontiers in Immunology
- Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies
- (2020) Takashi Kei Kishimoto Frontiers in Immunology
- Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity
- (2018) Ronit Mazor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tolerogenic Nanoparticles Induce Antigen-Specific Regulatory T Cells and Provide Therapeutic Efficacy and Transferrable Tolerance against Experimental Autoimmune Encephalomyelitis
- (2018) Robert A. LaMothe et al. Frontiers in Immunology
- Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration
- (2018) Amine Meliani et al. Nature Communications
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- 2016 updated EULAR evidence-based recommendations for the management of gout
- (2016) P Richette et al. ANNALS OF THE RHEUMATIC DISEASES
- Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation
- (2016) Ai-Hong Zhang et al. CELLULAR IMMUNOLOGY
- Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
- (2016) Takashi K. Kishimoto et al. Nature Nanotechnology
- Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
- (2015) J. N. Mahlangu et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- New FDA Draft Guidance on Immunogenicity
- (2014) Ashwin Parenky et al. AAPS Journal
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
- (2014) Roberto A. Maldonado et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
- (2014) Peter E Lipsky et al. ARTHRITIS RESEARCH & THERAPY
- Mammalian target of rapamycin inhibitor-associated stomatitis
- (2013) Christine B Boers-Doets et al. Future Oncology
- Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
- (2013) Herbert SB Baraf et al. ARTHRITIS RESEARCH & THERAPY
- Pegloticase and Chronic Gout--Reply
- (2011) J. S. Sundy et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started